ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Second Sight Medical Products Inc

Second Sight Medical Products Inc (EYES)

4.14
0.00
(0.00%)
At close: July 15 4:00PM
4.14
0.00
( 0.00% )

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
4.14
Bid
4.13
Ask
4.22
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
4.14
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
51,025,000
Dividend Yield
-
PE Ratio
-2.65
Earnings Per Share (EPS)
-0.5
Revenue
-
Net Profit
-25.65M

About Second Sight Medical Products Inc

Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. T... Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States. Show more

Sector
Med, Dental, Hosp Eq-whsl
Industry
Med, Dental, Hosp Eq-whsl
Website
Headquarters
Emeryville, California, USA
Founded
1970

EYES Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SVRESaverOne 2014 Ltd
$ 0.5952
(34.02%)
2.52M
WNWMeiwu Technology Company Ltd
$ 1.15
(29.21%)
1.29M
AZA2Z Smart Technologies Corporation
$ 0.89
(12.66%)
754
IPDNProfessional Diversity Network Inc
$ 0.5386
(11.98%)
591
BCDABioCardia Inc
$ 3.84
(10.98%)
548.1k
CYNCYNGN Inc
$ 8.07
(-12.64%)
96.69k
KTTAPasithea Therapeutics Corporation
$ 5.50
(-9.24%)
1.5k
SQFTPresidio Property Trust Inc
$ 0.703
(-6.71%)
135
GNLNGreenlane Holdings Inc
$ 0.2722
(-6.14%)
12.6k
PDYNPalladyne AI Corporation
$ 2.0011
(-6.05%)
601
TSLATesla Inc
$ 253.07
(0.09%)
3.9M
AAPLApple Inc
$ 234.71
(0.12%)
3.78M
SVRESaverOne 2014 Ltd
$ 0.5952
(34.02%)
2.52M
FFIEFaraday Future Intelligent Electric Inc
$ 0.5245
(0.76%)
2.47M
NVDANVIDIA Corporation
$ 128.43
(0.00%)
2.08M

EYES Discussion

View Posts
Bieldog Bieldog 2 years ago
this stock will shoot up to $15 in one month!!! go VANI
๐Ÿ‘๏ธ0
222 222 2 years ago
A tremendous move and nobody comments?
๐Ÿ‘๏ธ0
ernie44 ernie44 2 years ago
interesting history
๐Ÿ‘๏ธ0
IPO$ IPO$ 2 years ago
Stock is trading here itโ€™s 52 week low which looks like potential here in my opinion.
๐Ÿ‘๏ธ0
FORDGT FORDGT 2 years ago
That's your call. Or call your broker for up to date information. GL
๐Ÿ‘๏ธ0
IPO$ IPO$ 2 years ago
Do you recommend buying or selling the stock?
๐Ÿ‘๏ธ0
FORDGT FORDGT 3 years ago
In August, 2011 the (EYES) Second Sight Medical Products, Inc. SqueezeTrigger Price was $0.00. If you had purchased EYES, the trade would have gained 270,950.00% as of today's price of $2.71
๐Ÿ‘๏ธ0
jhdf51 jhdf51 3 years ago
down the toilet
๐Ÿ‘๏ธ0
Biggiee Biggiee 3 years ago
Buyers exhausted yesterday and now shorts easily fill the vacuum below to plunge the price, which in turn pressures bag holders to concede and sell, weighing the price even lower. Shame these companies in need of money turn to the wolves to pillage the retail guy, but hey, thatโ€™s always been the business.
Meat grinder.
Poorly played, $EYES
๐Ÿ‘๏ธ0
Biggiee Biggiee 3 years ago
It appears someone was waiting to dump shares on such an occasion. Unfortunately there isnโ€™t enough buyers to absorb it and squashed the MOMO.
Pity, I like what this company has to offer, but appears they made some toxic dealings since that last mega run. Shame really.
$EYES
๐Ÿ‘๏ธ0
shimanoman shimanoman 3 years ago
How the F is this down to $4.14 a 3 month low after this news?? The offering was priced at $5.00! 39mil OS, .. this makes zero sense
๐Ÿ‘๏ธ0
Jake L Jake L 3 years ago
EYES - HUGE NEWS JUST RELEASED

๐Ÿ‘๏ธ0
mth383s mth383s 3 years ago
Warrants are amazing.
๐Ÿ‘๏ธ0
blackpilled blackpilled 3 years ago
Dang dude that is so cool.
๐Ÿ‘๏ธ0
Supersue Supersue 3 years ago
EYES Gets patent.I'm loaded with warrants and stock.Last time I bought the warrants they went from .47 t0 like $8.00 in two days.I made so much money it was unbelievable.
๐Ÿ‘๏ธ0
Glider549 Glider549 3 years ago
Bummer you moved on.
๐Ÿ‘๏ธ0
Glider549 Glider549 3 years ago
You nailed it.
๐Ÿ‘๏ธ0
Biggiee Biggiee 3 years ago
$4 breakโ€ฆ volume trickling inโ€ฆ here we go?
EYES
๐Ÿ‘๏ธ0
Biggiee Biggiee 3 years ago
Starting position @$3.65. This looks ready for another run soon. Hopefully itโ€™s not forgotten.
$EYES
๐Ÿ‘๏ธ0
Bieldog Bieldog 3 years ago
Its toast moving on !!
๐Ÿ‘๏ธ0
Bieldog Bieldog 3 years ago
Good news on the horizon patience will pay off.


Go eyes !!
๐Ÿ‘๏ธ0
Big Barnie Big Barnie 3 years ago
MORE DILUTION
๐Ÿ‘๏ธ0
ClayTrader ClayTrader 3 years ago
* * $EYES Video Chart 06-04-2021 * *

Link to Video - click here to watch the technical chart video

๐Ÿ‘๏ธ0
Big Barnie Big Barnie 3 years ago
WOW!!!!!!

EYES has become a totally manipulated trading stock
๐Ÿ‘๏ธ0
ClayTrader ClayTrader 3 years ago
* * $EYES Video Chart 05-12-2021 * *

Link to Video - click here to watch the technical chart video

๐Ÿ‘๏ธ0
AlphaStockNews AlphaStockNews 3 years ago
$EYES is screaming for the top after announcing positive results from its two-year Orion study in the majority of patients. https://cnafinance.com/second-sight-medical-eyes-stock-climbs-on-study-results/
๐Ÿ‘๏ธ0
conix conix 3 years ago
EYES and CUBT should get together


Looks like they would be a good fit.

From CEO blog at www.curativebiotech.com


Sometimes starting big is the right decision (CUB)

AMD (age related macular degeneration) results from damage to the macula, the part of the eye responsible for central vision and the ability to see clearly. Most cases of macular degeneration occur as part of the aging process. AMD is a progressive retinal disease, usually occurring at age 55 years or older. There are two forms of AMD โ€“ dry and wet. All cases begin as the dry form, but 10 to 15 percent progress to the wet form, which can result in sudden and severe central vision loss.

Wet AMD accounts for as much as 90 percent of all AMD-related blindness and is thought to begin when blood vessels form abnormally at the back of the eye through a process called angiogenesis. The blood vessels leak blood or fluid in the macula and form scars that cause central vision to deteriorate and may result in permanent blind spots.

About 200,000 new cases of wet AMD are diagnosed each year in North America due to the aging baby boomer population. There are probably 3 million patients already in North America alone.

There are two widely used FDA approved โ€œtreatmentsโ€ for wet AMD; Lucentis, from Roche/Genentech and Eylea from Regeneron. Eylea is by far the most prescribed. Both are injected directly into the eye(s) of patients on a regular basis to maintain effectiveness. Both drugs basically work by blocking the action of VEGF (vascular endothelial growth factor) whose job is to vascularize (make new blood vessels) in the eye. When that process goes bad, vision is seriously impaired. You can think of these treatments as a sort of temporary patch that fixes leaky vessels and stops new leaks from occurring. On its web site Lucentis describes the possible benefit to patients as โ€œmaintainingโ€ their vision. Maintained is defined as losing less than 15 letters or 3 lines on the eye chart after 1 year. Combined, the drugs are multi-billion dollar a year products.

If you are reading this blog then you probably know that Curative has licensed from the NEI (National Eye Institute) what we believe will be a next generation treatment for degenerative eye diseases without the necessity of eye injections. We have licensed a discovery which allows for metformin, one of the most prescribed drugs in the world, to be reformulated into an eye drop for daily use to actually change the conditions in the eye which allow for the angiogenesis which is at the heart of the problems created by wet AMD. We have already started working on our reformulation, and expect to file an IND with the FDA to begin human trials before the end of the year. If you follow us then you also know that Dr. Kapil Bharti, the lead inventor on all of the licensed patents (pending) from NEI at NIH, has joined our Scientific and Clinical Advisory Board to help guide the program. His expertise and insights are invaluable.

Wet AMD is not an orphan or rare disease. And while our initial focus for this product was the rare disease Stargardtโ€™s, we have decided to move forward with wet AMD as our first indication. We still intend to use the drug to treat Stargardtโ€™s patients. A good deal of our non-clinical and clinical work on wet AMD should be applicable for our eventual filing to treat Stargardtโ€™s if the wet AMD drug receives marketing approval from the FDA and/or other national regulatory bodies. But our Advisory Board and Management came to the conclusion that because of the much larger number of patients it will be much easier/quicker/less expensive to recruit the human trials and move towards FDA approval in Wet AMD. Because Metformin is already an approved drug with decades of safety data, we may be eligible for the 505B2 pathway at the FDA, specifically created for new formulations and/or routes of administration of approved drugs. Of course here, in addition to a reformulation and a new route of administration (eye drop instead of pill) we are also proposing use for a new indication. Currently metformin is prescribed to help treat diabetes.

So I thought it was important to explain to our shareholders that while we Are focused on rare or orphan diseases, often our drugs will also be capable of treating disease in larger patient populations. When we do start a program on one of those larger indications, we will always look to leverage all of the work to be able to circle back and treat the orphan disease also. Wet AMD to Stargardtโ€™s is a perfect example and also a good example of when starting big is the right decision.
๐Ÿ‘๏ธ0
SwingLong SwingLong 3 years ago
Lmao... who still holding...
๐Ÿ‘๏ธ0
SwingLong SwingLong 3 years ago
Will this jump Friday with options expiring?
๐Ÿ‘๏ธ0
Jess070283 Jess070283 3 years ago
Time to load up!$$$
๐Ÿ‘๏ธ0
georgie18 georgie18 3 years ago
EYES...$9.14...in the P/M...:party:
[7:06 AM]
georgie18 โ€” Yesterday at 5:19 AM
EYES...$7.40...Bidding the Lower Band for possible entry on the dip off the 8K...:party:
๐Ÿ‘๏ธ0
georgie18 georgie18 3 years ago
Thank you...
๐Ÿ‘๏ธ0
ClayTrader ClayTrader 3 years ago
* * $EYES Video Chart 04-06-2021 * *

Link to Video - click here to watch the technical chart video

๐Ÿ‘๏ธ0
jchords jchords 3 years ago
Good call
๐Ÿ‘๏ธ0
georgie18 georgie18 3 years ago
EYES...$7.40...Bidding the Lower Band for possible entry on the dip off the 8K...

https://www.otcmarkets.com/filing/html?id=14851937&guid=ow0pUp_yX-Kwkth

Chart... https://schrts.co/mPycAPAf

๐Ÿ‘๏ธ0
Skidoonut Skidoonut 3 years ago
I believe they have a better offer, too blow up the deal with pixium is significant. Pixium owns a controlling stake in eyes and i believe the rapid drop is due to them selling that position 6million shares give or take. Also blowing the deal up with the financing company to me means that they are not worried about financing going forward they have a decent amount of cash on hand. That being said I expect some news possibly tomorrow to clarify business plans moving forward, once the offering is closed on or before 3-26.
Nothing really changes here except the merger with pixium, I do believe this is still a diamond in the rough.

Skidoo
๐Ÿ‘๏ธ0
bcapps66 bcapps66 3 years ago
I got out around $11. The offering changes things a bit in my opinion and as seen with the price drop. I'll keep my eye on it. Still a low floater..
๐Ÿ‘๏ธ0
SwingLong SwingLong 3 years ago
LOL sad case
๐Ÿ‘๏ธ0
BigMoneyAtl BigMoneyAtl 3 years ago
Great news if no merger happens. Eyes get short end of the stick with the merger. Eyes shares will be diluted if merger goes thru.
๐Ÿ‘๏ธ0
Big Barnie Big Barnie 3 years ago
It appears to me that the merger is in jeopardy

Legal issues could also be forthcoming

While I believe mgmt made the right decision to raise capital at
this inflated PPS, I am not insure what the future will be.

This raise is just a band aid as much more capital and/or a partner is needed

Any serious comments
๐Ÿ‘๏ธ0
peterus peterus 3 years ago
think it will go back up
๐Ÿ‘๏ธ0
SwingLong SwingLong 3 years ago
You think it will jump back or will it be a long ride till that happens?
๐Ÿ‘๏ธ0
peterus peterus 3 years ago
closed $11 yesterday
๐Ÿ‘๏ธ0
peterus peterus 3 years ago
4.65 mil shares at a $6
what a joke
๐Ÿ‘๏ธ0
SwingLong SwingLong 3 years ago
Think this pig is done or a spike is on its way?
๐Ÿ‘๏ธ0
bcapps66 bcapps66 3 years ago
Low floater....
๐Ÿ‘๏ธ0
SwingLong SwingLong 3 years ago
Ouch, whatโ€™s up with this...

The swings are insane, supper low dips, supper high highs.... weird...
๐Ÿ‘๏ธ0
Afhotjer4u Afhotjer4u 3 years ago
Go Eyes, Go
๐Ÿ‘๏ธ0
ClayTrader ClayTrader 3 years ago
* * $EYES Video Chart 03-18-2021 * *

Link to Video - click here to watch the technical chart video

๐Ÿ‘๏ธ0
bcapps66 bcapps66 3 years ago
Not so easy....wild day today
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock